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A patient with acute lymphoblastic leukemia repeatedly developed hypoglycemia during chemotherapy.
Comparison of serum glucose trends between chemotherapy with and without L-asparaginase (L-Asp)
demonstrated a strong association between L-Asp and hypoglycemia. Critical blood sampling during hypoglycemia
indicated hyperinsulinism, suggesting that L-Asp induced hypoglycemia in the patient through inappropriate insulin
secretion. Identification of hypoglycemia as an adverse effect will enable clinicians to understand and develop
appropriate strategies for L-Asp use in chemotherapy regimens.
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levelsBackground
The enzyme L-asparaginase (L-Asp) has been com-
monly used for treatment of childhood acute lympho-
blastic leukemia (ALL) for more than 30 years [1-3].
Because of its unique pharmacological features and
historically improved treatment outcomes, L-Asp
forms an essential part of ALL regimens worldwide
[4]. However, many adverse effects of L-Asp have
been documented, such as coagulopathy, acute pan-
creatitis, allergic reaction, hyperlipidemia, hyperammo-
nemia, hepatotoxicity, and hyperglycemia [5-8].
Therefore, clinicians must carefully monitor patients
treated with L-Asp for these adverse effects. Until
date, hypoglycemia has not been formally reported as
an adverse effect of L-Asp. We report, for the first
time, a case of hypoglycemia associated with L-Asp
use.Case presentation
A 5-year-old girl with Philadelphia chromosome-positive
ALL was treated with the induction therapy protocol of
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reproduction in any medium, provided the orL99-15 for high-risk patients. Therapy included pred-
nisolone, vincristine, cyclophosphamide, daunorubicin,
triple intrathecal injection, and L-Asp (Kyowa Hakko
Kirin, Tokyo, Japan) [9]. The patient was administered
6000 IU/m2 of native Escherichia coli L-Asp on days
16, 18, 20, 23, 25, 27, 30, 32, and 34 of treatment. On
day 18, she developed fasting hypoglycemia (glucose,
56 mg/dL) with severe hunger and without other
signs or symptoms such as tremor, palpitation, anx-
iety, sweating, or paresthesias. On day 27 (fasting
serum glucose level, 50 mg/dL), critical blood sam-
pling showed 6 U/mL of immunoreactive insulin,
0.47 mEq/L of free fatty acids, and 27 mol/L of ke-
tone bodies. She repeatedly developed fasting
hypoglycemia (glucose, 38–65 mg/dL) until day 37,
without serious complications (Figure 1). Five days
after the last L-Asp administration, her fasting glucose
levels were elevated from 73 to 87 mg/dL. During in-
duction therapy, fasting glucose levels were always
measured before the morning steroid dose.
TCCSG L99-15 intensification-1, including high-dose
cytarabine, methylprednisolone, L-Asp, and triple intra-
thecal injection, was started with daily imatinib. Thereafter,
HR blocks of Berlin–Frankfurt–München (BFM) 2000 were
administered. The HR blocks included cytarabine,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Fasting serum glucose levels during induction therapy with L-Asp and protocol III without L-Asp (Day 1–16). Monitoring of
fasting serum glucose shows hypoglycemia during the estimated L-asp active period, displayed as the zone between dashed lines (−−−−). PSL
denotes predonisolone; VCR, vincristine; CPA, cyclophosphamide; DNR, daunorubicin; L-Asp, L-asparaginase; IT, intrathecal injection; DEX,
dexamethasone; DOX, doxorubicin; and Das, dasatinib.
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cin, cyclophosphamide, dexamethasone, and L-Asp [10].
Daily dasatinib was included in the HR blocks instead
of imatinib to avoid allergic reaction during TCCSG
intensification-1. L-Asp was administered on day 5 of
intensification-1 and days 6 and 11 of the HR block
therapy. During early treatment days before L-Asp
administration, the patient repeatedly developed fast-
ing hyperglycemia (glucose, up to 132 mg/dL). After
L-Asp administration, she repeatedly experienced fast-
ing hypoglycemia and was provided with supplemental
food and intravenous fluid containing dextrose to pre-
vent severe hypoglycemia.
At the end of the third HR block, she suffered acute
pancreatitis. When chemotherapy was resumed after
2 weeks of treatment for pancreatitis, L-Asp was
excluded from protocol III of BFM 2000 (reinduction
therapy), which included dexamethasone, vincristine,
doxorubicin, cyclophosphamide, cytarabine, mercapto-
purine, and intrathecal methotrexate administration.
During protocol III, the patient did not experience
hypoglycemia and had relatively high fasting glucose
levels, up to 114 mg/dL (Figure 1).
Glucose levels during the estimated L-Asp active period
were significantly lower than those before and after the in-
duction therapy period (Student t-test, p< 0.05). The esti-
mated L-Asp active period was defined as that from the
first administration to 4 days after the last administration
during induction therapy, given that the patient’s fibrino-
gen level decreased with L-Asp and spontaneously recov-
ered 5 days after the last L-Asp administration. This
estimation is supported by a report that L-Asp activity is
retained for 3 days in the BFM 2000 protocol, where
5000 IU/mL L-Asp is administered at 3-day intervals [11].Thereafter, a linear regression model was used to identify
the relationship between fasting glucose levels, L-Asp, and
glucocorticoid potency during induction therapy and
protocol III, with the same treatment structure as that of
induction therapy. Variables were entered into a least-
squares model. Prednisolone and dexamethasone potency
was converted to hydrocortisone potency using 4:1 and
20:1 ratios, respectively [12]. Fasting glucose levels before
and after the estimated L-Asp active period of induction
therapy and during days 1–16 of protocol III were treated
as values without L-Asp, whereas fasting glucose levels
during the estimated L-Asp active period were treated as
values with L-Asp. Linear regression analysis showed that
fasting glucose levels were significantly lower during the L-
Asp active period (42.91 mg/dL, p< 0.001), and the hyper-
glycemic effect of glucocorticoids was significant (glucose,
0.084 mg/dL per mg hydrocortisone equivalence, p=0.015),
indicating the following equation: glucose=0.084× [steroid
potency]−42.91× [L-Asp use (1 or 0)] +78.96 (Figure 2).
We confirmed that L-Asp activity was therapeutic dur-
ing fasting hypoglycemia in the first HR block. L-Asp
activity was 0.709 U/mL on day 10, 0.674 U/mL on day
11, and 1.78 U/mL on day 12, where 25000 U/m2 of L-
Asp was administered on days 6 and 11. L-Asp activity
was measured using the enzyme coupling methods
described by Tsurusawa et al. [13,14]. L-Asp activity
above 0.1 U/mL was generally considered therapeutic.
The detection limit of this method was 0.002 U/mL.
Conclusions
During ALL treatment, glucose levels are routinely mon-
itored because many patients develop hyperglycemia,
presumably because of glucocorticoids and L-Asp. Unex-
pectedly, our patient experienced repeated fasting
Figure 2 Linear regression analysis of fasting glucose, L-Asp, and glucocorticoid potency during induction therapy and protocol III.
Linear regression analysis shows significant hypoglycemia during L-Asp use (p< 0.001) and a significant hyperglycemic effect of glucocorticoids
(p= 0.015). Fasting glucose levels were plotted with L-Asp (□) and without L-Asp (●). Glucocorticoid potency is calculated as hydrocortisone
equivalence with conversion ratios of 4:1 (prednisolone) and 20:1 (dexamethasone). L-Asp denotes L-asparaginase.
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and HR block therapy. From induction through HR
block therapy, L-Asp and steroids were both used and
hypoglycemia was always observed after L-Asp use.
Given the time relation between L-Asp administration
and hypoglycemia, we hypothesized that our patient
experienced L-Asp–induced hypoglycemia. Firstly, we
compared fasting glucose levels with L-Asp and without
L-Asp during induction (Student T-test), showing that
those with L-Asp were significantly lower. After HR
block therapy, L-Asp was excluded from protocol III be-
cause of the development of pancreatitis. Then, we com-
pared fasting glucose levels during induction and first
half of protocol III, the same backbone of treatment with
and without L-Asp, respectively.
The following questions are to be answered: 1) How
does L-Asp induce hypoglycemia? 2) Is there any use of
other agents that might affect fasting glucose levels? 3)
Why has hypoglycemia not been commonly seen or
reported?
In response to the first question, inappropriate insulin
secretion, normal free fatty acids, and low ketone bodies
during severe hypoglycemia indicated hyperinsulinism,
suggesting that L-Asp induced hypoglycemia through in-
sulin hypersecretion. Regarding the second question, be-
sides L-Asp use, there were the following differences
between induction therapy and day 1–16 of protocol III;
doxorubicin was used in protocol III instead of daunorubi-
cin in induction therapy, and dasatinib was used inprotocol III but not in induction therapy. Dasatinib has
been not documented to cause the adverse effect of hyper-
glycemia or hypoglycemia. There was no use of other
drugs that potentially induce hypoglycemia or hypergly-
cemia during these periods, such as non-steroidal anti-
inflammatory drugs, antibacterial agents, or imatinib [15].
To the third question, there are few reports focusing on
fasting glucose levels in the morning [6,7]. Glucocorticoids
are known to induce hyperglycemia through insulin resist-
ance and gluconeogenesis during induction therapy for
childhood ALL [16]. We suspect that parallel use of
glucocorticoids may mask the hypoglycemic effect of
L-Asp. Since different glucocorticoid agents were used in
these two regimens, we treated glucocorticoids as an inde-
pendent parameter with glucocorticoid potency conver-
sion. Linear regression model showed a significant L-Asp
hypoglycemic effect as well as glucocorticoid hypergly-
cemic effect. There was no significant interaction between
L-Asp and glucocorticoids. There remains a concern with
validity of glucocorticoid potency conversion for hypergly-
cemic effect. To overcome the limitation of this case re-
port, further clinical data focusing on hypoglycemia are
needed.
Use of L-Asp has recently become even more com-
mon in the adult ALL regimens [17]. We believe that
in addition to the effect of L-Asp on leukemic cells, it
is important to pay more attention to its pharmaco-
logical features and physiological mechanisms. Greater
knowledge of these effects will enable clinicians to
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L-Asp use in chemotherapy regimens.
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